These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 35350978)

  • 1. CD63-positive extracellular vesicles are potential diagnostic biomarkers of pancreatic ductal adenocarcinoma.
    Odaka H; Hiemori K; Shimoda A; Akiyoshi K; Tateno H
    BMC Gastroenterol; 2022 Mar; 22(1):153. PubMed ID: 35350978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular vesicle-derived microRNAs in pancreatic juice as biomarkers for detection of pancreatic ductal adenocarcinoma.
    Nesteruk K; Levink IJM; de Vries E; Visser IJ; Peppelenbosch MP; Cahen DL; Fuhler GM; Bruno MJ
    Pancreatology; 2022 Jun; 22(5):626-635. PubMed ID: 35613957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-derived extracellular vesicles are increased in sera of Alzheimer's disease patients, as revealed by Tim4-based assays.
    Odaka H; Hiemori K; Shimoda A; Akiyoshi K; Tateno H
    FEBS Open Bio; 2021 Mar; 11(3):741-752. PubMed ID: 33345458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating cancer-associated extracellular vesicles as early detection and recurrence biomarkers for pancreatic cancer.
    Yoshioka Y; Shimomura M; Saito K; Ishii H; Doki Y; Eguchi H; Nakatsura T; Itoi T; Kuroda M; Mori M; Ochiya T
    Cancer Sci; 2022 Oct; 113(10):3498-3509. PubMed ID: 35848896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-18a and miR-106a Signatures in Plasma Small EVs Are Promising Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma.
    Xu X; Bhandari K; Xu C; Morris K; Ding WQ
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
    Zeöld A; Sándor GO; Kiss A; Soós AÁ; Tölgyes T; Bursics A; Szűcs Á; Harsányi L; Kittel Á; Gézsi A; Buzás EI; Wiener Z
    Cell Mol Life Sci; 2021 Mar; 78(6):3005-3020. PubMed ID: 33237353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Exosome-based Transcriptomic Signature for Noninvasive, Early Detection of Patients With Pancreatic Ductal Adenocarcinoma: A Multicenter Cohort Study.
    Nakamura K; Zhu Z; Roy S; Jun E; Han H; Munoz RM; Nishiwada S; Sharma G; Cridebring D; Zenhausern F; Kim S; Roe DJ; Darabi S; Han IW; Evans DB; Yamada S; Demeure MJ; Becerra C; Celinski SA; Borazanci E; Tsai S; Kodera Y; Park JO; Bolton JS; Wang X; Kim SC; Von Hoff D; Goel A
    Gastroenterology; 2022 Nov; 163(5):1252-1266.e2. PubMed ID: 35850192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma extracellular vesicle messenger RNA profiling identifies prognostic EV signature for non-invasive risk stratification for survival prediction of patients with pancreatic ductal adenocarcinoma.
    Han Y; Drobisch P; Krüger A; William D; Grützmann K; Böthig L; Polster H; Seifert L; Seifert AM; Distler M; Pecqueux M; Riediger C; Plodeck V; Nebelung H; Weber GF; Pilarsky C; Kahlert U; Hinz U; Roth S; Hackert T; Weitz J; Wong FC; Kahlert C
    J Hematol Oncol; 2023 Feb; 16(1):7. PubMed ID: 36737824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Size and Concentration of Extracellular Vesicles in Pancreatic Juice From Patients With Pancreatic Ductal Adenocarcinoma.
    Nesteruk K; Levink IJM; Dits NFJ; Cahen DL; Peppelenbosch MP; Bruno MJ; Fuhler GM
    Clin Transl Gastroenterol; 2022 Feb; 13(3):e00465. PubMed ID: 35363220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrin α6A (ITGA6A)-type Splice Variant in Extracellular Vesicles Has a Potential as a Novel Marker of the Early Recurrence of Pancreatic Cancer.
    Asada T; Nakahata S; Fauzi YR; Ichikawa T; Inoue K; Shibata N; Fujii Y; Imamura N; Hiyoshi M; Nanashima A; Morishita K
    Anticancer Res; 2022 Apr; 42(4):1763-1775. PubMed ID: 35346995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma.
    Liu DSK; Puik JR; Patel BY; Venø MT; Vahabi M; Prado MM; Webber JP; Rees E; Upton FM; Bennett K; Blaker C; Immordino B; Comandatore A; Morelli L; Sivakumar S; Swijnenburg RJ; Besselink MG; Jiao LR; Kazemier G; Giovannetti E; Krell J; Frampton AE
    J Exp Clin Cancer Res; 2024 Jul; 43(1):189. PubMed ID: 38978141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
    Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
    Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased circulating platelet-derived extracellular vesicles in severe COVID-19 disease.
    Helin T; Palviainen M; Lemponen M; Maaninka K; Siljander P; Joutsi-Korhonen L
    Platelets; 2024 Dec; 35(1):2313362. PubMed ID: 38380806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer.
    Takahashi K; Ota Y; Kogure T; Suzuki Y; Iwamoto H; Yamakita K; Kitano Y; Fujii S; Haneda M; Patel T; Ota T
    Cancer Sci; 2020 Jan; 111(1):98-111. PubMed ID: 31715081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.
    Guo X; Lv X; Fang C; Lv X; Wang F; Wang D; Zhao J; Ma Y; Xue Y; Bai Q; Yao X; Chen Y
    Int J Cancer; 2016 Oct; 139(8):1821-9. PubMed ID: 27281120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma.
    Takayama R; Nakagawa H; Sawaki A; Mizuno N; Kawai H; Tajika M; Yatabe Y; Matsuo K; Uehara R; Ono K; Nakamura Y; Yamao K
    J Gastroenterol; 2010; 45(1):52-9. PubMed ID: 19789838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers.
    Kim J; Bamlet WR; Oberg AL; Chaffee KG; Donahue G; Cao XJ; Chari S; Garcia BA; Petersen GM; Zaret KS
    Sci Transl Med; 2017 Jul; 9(398):. PubMed ID: 28701476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracellular vesicles from pancreatic ductal adenocarcinoma endoscopic ultrasound-fine needle aspiration samples contain a protein barcode.
    Inoue H; Eguchi A; Kobayashi Y; Usugi E; Yamada R; Tsuboi J; Akuta T; Horiki N; Iwasa M; Takei Y
    J Hepatobiliary Pancreat Sci; 2022 Mar; 29(3):394-403. PubMed ID: 34555251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.